PCNA and triple-negative breast carcinoma: Consistent with this view, downregulation of endogenous PCNA in pancreas, prostate, breast and brain tumor cell lines by a siRNA approach and the blockade of NKp44-PCNA interaction in triple negative breast cancer cells by a monoclonal antibody increased NK cytotoxicity and tumor killing (155).